BIA
BPMC

Bell Investment Advisors’s Blueprint Medicines BPMC Stock Holding History

Bell Investment Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11
Closed -$696 – 1934
2023
Q2 		$696 Hold
11
– – ﹤0.01% 1694
2023
Q1 		$495 Buy
+11
New +$496 ﹤0.01% 1836
2021
Q4 		– Sell
-15
Closed -$2K – 1786
2021
Q3 		$2K Buy
+15
New +$1.4K ﹤0.01% 1028

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bell Investment Advisors's BPMC Position: Q3 2023 in Review

Bell Investment Advisors sold out of Blueprint Medicines (BPMC) in Q3 2023, closing a stake of 11 shares — an estimated $696 sold.

Bell Investment Advisors first reported a position in BPMC in Q3 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2021. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2023.

  • Bell Investment Advisors reported no remaining Blueprint Medicines position as of Q3 2023 after selling out during the quarter.
  • Bell Investment Advisors sold 11 Blueprint Medicines shares in Q3 2023, an estimated $696.
  • Bell Investment Advisors first reported a position in Blueprint Medicines in Q3 2021 and held it in 3 quarters.
  • Bell Investment Advisors's Blueprint Medicines position peaked at $2K in Q3 2021.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2023.

Based on Bell Investment Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.